Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Annalisa Guida

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
The Oncologist|February 8, 2021
The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell CarcinomaElie Rassy, Luigi Cerbone, Edouard Auclin, et al.
Cancers|March 25, 2022
Looking for a Simplified Diagnostic Model to Identify Potentially Lethal Cases of Prostate Cancer at Initial Diagnosis: An ImGO Pilot StudySerena Macrini, Simona Francesconi, Cecilia Caprera, et al.
Clinical Genitourinary Cancer|November 7, 2018
Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 StudyCristina Masini, Maria Giuseppa Vitale, Marco Maruzzo, et al.
Clinical Genitourinary Cancer|October 15, 2024
Efficacy and Safety of Pembrolizumab plus Axitinib combination for Metastatic Renal Cell Carcinoma in a Real-World Scenario: Data From the Prospective ProPAXI StudyAnnalisa Guida, Alessio Gili, Claudia Mosillo, et al.
Future Oncology (London, England)|March 20, 2019
Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancerOrazio Caffo, Gaetano Facchini, Elisa Biasco, et al.
Journal of Kidney Cancer and VHL|October 20, 2025
Meet-URO Score Validation in Real-world Patients with Metastatic Renal Cell Carcinoma Receiving First-line Pembrolizumab Plus axitinib: A Subanalysis of the Prospective ProPAXI StudyGiulia Airò, Annalisa Guida, Alessio Gili, et al.
Pathology Oncology Research : POR|July 12, 2017
The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign OutcomeFrancesco Massari, Chiara Ciccarese, Ondrej Hes, et al.
Leukemia & Lymphoma|June 21, 2012
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective studyAngelo M Carella, Carmino A de Souza, Stefano Luminari, et al.
BMC Cancer|July 21, 2017
Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014)Rodolfo Passalacqua, Silvia Lazzarelli, Maddalena Donini, et al.
Urologic Oncology|June 3, 2017
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancerRoberto Iacovelli, Maria Cossu Rocca, Luca Galli, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
The Oncologist|February 8, 2021
The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell CarcinomaElie Rassy, Luigi Cerbone, Edouard Auclin, et al.
Cancers|March 25, 2022
Looking for a Simplified Diagnostic Model to Identify Potentially Lethal Cases of Prostate Cancer at Initial Diagnosis: An ImGO Pilot StudySerena Macrini, Simona Francesconi, Cecilia Caprera, et al.
Clinical Genitourinary Cancer|November 7, 2018
Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 StudyCristina Masini, Maria Giuseppa Vitale, Marco Maruzzo, et al.
Clinical Genitourinary Cancer|October 15, 2024
Efficacy and Safety of Pembrolizumab plus Axitinib combination for Metastatic Renal Cell Carcinoma in a Real-World Scenario: Data From the Prospective ProPAXI StudyAnnalisa Guida, Alessio Gili, Claudia Mosillo, et al.
Future Oncology (London, England)|March 20, 2019
Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancerOrazio Caffo, Gaetano Facchini, Elisa Biasco, et al.
Journal of Kidney Cancer and VHL|October 20, 2025
Meet-URO Score Validation in Real-world Patients with Metastatic Renal Cell Carcinoma Receiving First-line Pembrolizumab Plus axitinib: A Subanalysis of the Prospective ProPAXI StudyGiulia Airò, Annalisa Guida, Alessio Gili, et al.
Pathology Oncology Research : POR|July 12, 2017
The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign OutcomeFrancesco Massari, Chiara Ciccarese, Ondrej Hes, et al.
Leukemia & Lymphoma|June 21, 2012
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective studyAngelo M Carella, Carmino A de Souza, Stefano Luminari, et al.
BMC Cancer|July 21, 2017
Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014)Rodolfo Passalacqua, Silvia Lazzarelli, Maddalena Donini, et al.
Urologic Oncology|June 3, 2017
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancerRoberto Iacovelli, Maria Cossu Rocca, Luca Galli, et al.
Pageof 5